IMMU

[setravis]

 

Updated chart.......

52wk Range: 1.92 - 6.12
Volume: 7,296,309
Avg Vol (3m): 891,097

Technicals
Close Above the 50-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
45.95%above 13-day MA
33.46%above 50-day MA
RS Rating: 11 

Fundamentals
Key Data:
Market Cap (M): $172.64 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/05/2007
Last Analyst Rating: Buy

[setravis]

(IMMU).......
PRESENTS POSITIVE PRECLINICAL DATA: Immunomedics, Inc. (IMMU) announced that its
humanized anti-CD74 antibody, milatuzumab, showed promising therapeutic activity for B-cell
lymphoma in animal models. This activity can be enhanced when combined with anti-CD20 antibodies.
These preclinical results were presented at the AACR-NCI-EORTC International Conference
on Molecular Targets and Cancer Therapeutics in San Francisco, CA. Milatuzumab was
tested in comparison to and in combination with veltuzumab, a humanized anti-CD20 antibody
from Immunomedics, in mice bearing human B-cell lymphoma transplants. Median survival time
(MST) for untreated animals was 36 days. Veltuzumab extended MST to 70 days, while milatuzumab
treatment increased survival further to 90.5 days. However, when both antibodies were
combined, MST improved significantly to 113 days.

[setravis]

Since March of 09...this one ran wild...